This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.
ADME PK

Early Formulation (Pre-formulation) Screening Services

Addressing Formulation Issues Early

Poor solubility / low bioavailability are significant issues during drug discovery and development. It is reported that up to 75% of compounds currently under development are poorly water-soluble, with this figure rising to 90% for new chemical entities. This is of concern because solubility issues can result in the generation of misleading or inaccurate data, result in project delays and ultimately increase the overall cost of a project. Therefore, it is important to understand and address solubility issues early with appropriate formulation strategies.

Our parent company, Evotec, has considerable expertise in formulation and can expedite early phase formulation development from discovery to clinic. This spans from early formulation assessment through to CMC (Chemistry, Manufacturing and Control) capabilities with support for drug substance and drug product development and GMP manufacturing for Phase I to III clinical development programs.

Evotec’s early formulation group based in the UK is able to tackle your formulation problems during drug discovery and support the selection of prototypes for clinical phase, using small amounts of compound. The group has a wide range of capabilities and expertise to support your project.

Capabilities include:

  • Design of complex dose-vehicles in support of toxicological investigations
  • Spray drying
  • Film coating (pellets, tablets, capsules) and drug layering
  • Hot melt extrusion
  • Micronisation (ball / air jet milling)
  • Nano-suspension preparation
  • Lyophilisation
  • Emulsion development (SMEDDs/ SEDDs)
  • Liposomes
  • Microparticles
  • Analytical testing- lipolysis tests, in vitro dissolution tests using dynamic dissolution methods (first CRO in the world)
  • Ability to work on formulations planned for any route of administration (oral, pulmonary, dermal/transdermal, intra-ocular, parental)
  • Solid state characterisation ( SEM, XRPD, DVS, PSD, mDSC) and pH solubility profiling
  • Support of patent applications

Contact enquiries@cyprotex.com to discuss your formulation requirements.

Request a Quote
Speak to a Scientist
ADME-Tox Guides Pricing & Discounts

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close